Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase NA 1Phase 3 1Phase 2 1Phase 1 1

Status

Recruiting 3Unknown 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 4INDUSTRY 2

Study Type

Interventional 6

Sponsor

Cancer Type

Head & Neck 2Lymphoid 1Gastrointestinal 1

Conditions

Melanoma 28Carcinoma, Non-Small-Cell Lung 28Neoplasm Metastasis 23Carcinoma, Hepatocellular 22Colorectal Neoplasms 19Triple Negative Breast Neoplasms 16Pancreatic Neoplasms 15Neoplasms 15Stomach Neoplasms 14Squamous Cell Carcinoma of Head and Neck 13Nasopharyngeal Carcinoma 13Carcinoma, Renal Cell 13Uterine Cervical Neoplasms 10Rectal Neoplasms 10Lymphoma 8Esophageal Squamous Cell Carcinoma 7Esophageal Neoplasms 7Sarcoma 6Recurrence 6Lymphoma, Extranodal NK-T-Cell 6Lung Neoplasms 6Locally Advanced Rectal Cancer 6Breast Neoplasms 6Advanced Solid Tumor 6Ovarian Neoplasms 5Liver Neoplasms 5Glioblastoma 5Endometrial Neoplasms 5Cholangiocarcinoma 5Small Cell Lung Carcinoma 4

Interventions

Cyclophosphamide 153Dexamethasone 141Rituximab 85fludarabine 79Lenalidomide 72Cytarabine 70Bortezomib 64fludarabine phosphate 63Gemcitabine 62venetoclax 54Etoposide 53pomalidomide 52pembrolizumab 52Paclitaxel 48Cisplatin 48Carboplatin 48Peripheral Blood Stem Cell Transplantation 47Filgrastim 40Radiotherapy 39Busulfan 37Calcium Dobesilate 36Methotrexate 34Melphalan 34Bevacizumab 33carfilzomib 32Cyclosporine 32Azacitidine 32Mycophenolic Acid 30Vincristine 29Bendamustine Hydrochloride 29

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Recurrence × spartalizumab × Clear all
NCT02961101 2026-01-22

Anti-PD-1 Antibody Alone or in Combination With Decitabine/Chemotherapy in Relapsed or Refractory Malignancies

Chinese PLA General Hospital

Phase 1/2 Recruiting
250 enrolled

Neoplasms, Recurrence

NCT05662397 2025-02-04

A Study of HST-1011 Given as Monotherapy and in Combination With an Anti-PD1 Antibody

HotSpot Therapeutics, Inc

Phase 1/2 Active not recruiting
77 enrolled

Neoplasms, Recurrence

NCT05631886 2023-08-28

Combination of CAR-DC Vaccine and ICIs in Malignant Tumors

Chinese PLA General Hospital

Phase 1 Recruiting
10 enrolled
Lymphoid

Lymphoma, Neoplasm Metastasis, Recurrence

NCT02605967 2022-02-10

Safety and Efficacy Study of PDR001 in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma

Novartis

Phase 2 Completed
122 enrolled 28 charts
Head & Neck

Nasopharyngeal Carcinoma, Nasopharyngeal Neoplasms, Recurrence, Disorders of Sex Development

NCT04778956 2021-03-04

Toripalimab Plus Surgery vs Surgery Alone for Resectable Recurrent Nasopharyngeal Carcinoma

Sun Yat-sen University

Phase 3 Recruiting
218 enrolled
Head & Neck

Nasopharyngeal Carcinoma, Recurrence

NCT03914352 2019-04-16

A Novel Immunotherapy PD-1 Antiboty to Suppress Recurrence of HCC Combined With PVTT After Hepatic Resection

Cancer Hospital of Guangxi Medical University

Phase NA Unknown
40 enrolled
Gastrointestinal

Carcinoma, Hepatocellular, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡